RuddRA, SethP, DavidF, SchollL: Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep, 2016; 65:1445–1452.
2.
VozorisNT, O'DonnellDE, BellC, et al.: Incident opioid use is associated with risk of respiratory harm in non-palliative COPD. Eur Respir J, 2017; 49. PubMed PMID: 28275179.
3.
RayWA, ChungCP, MurrayKT, et al.: Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. JAMA, 2016; 315:2415–2423.
4.
NeutelCI, JohansenHL: Association between hypnotics use and increased mortality: Causation or confounding?. Eur J Clin Pharmacol, 2015; 71:637–642.
5.
NishimuraK, IzumiT, TsukinoM, OgaT: Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest, 2002; 121:1434–1440.
6.
MarciniukDD, GoodridgeD, HernandezP, et al.: Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: A Canadian Thoracic Society clinical practice guideline. Can Resp J, 2011; 18:69–78.
7.
RockerGM, SimpsonAC, YoungJ, et al.: Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: Patients' experiences and outcomes. CMAJ Open, 2013; 1:E27–E36.
8.
FreemantleN, MarstonL, WaltersK, et al.: Making inferences on treatment effects from real world data: Propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ, 2013; 347:f6409.
9.
WeeksC: Opioids prescribed for COPD may harm patients: Study. The Globe and Mail. July14, 2016.
10.
CurrowDC, McDonaldC, OatenS, et al.: Once-daily opioids for chronic dyspnea: A dose increment and pharmacovigilance study. J Pain Symptom Manage, 2011; 42:388–399.
11.
AbernethyAP, CurrowDC, FrithP, et al.: Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ, 2003; 327:523–528.
12.
VozorisNT, O'DonnellDE: The need to address increasing opioid use in elderly COPD patients. Expert Rev Respir Med, 2016; 10:245–248.
13.
VozorisNT, WangX, AustinPC, et al.: Adverse cardiac events associated with incident opioid drug use among older adults with COPD. Eur J Clin Pharmacol, 2017. PubMed PMID: 28664359.
14.
MasoudkabirF, SarrafzadeganN, EisenbergMJ: Effects of opium consumption on cardiometabolic diseases. Nat Rev Cardiol, 2013; 10:733–740.
15.
AsgaryS, SarrafzadeganN, NaderiGA, RozbehaniR: Effect of opium addiction on new and traditional cardiovascular risk factors: Do duration of addiction and route of administration matter?. Lipids Health Dis, 2008; 7:42.
16.
MahlerDA, O'DonnellDE: Recent advances in dyspnea. Chest, 2015; 147:232–241.
17.
JohnsonMJ, HuiD, CurrowDC: Opioids, exertion, and dyspnea: A review of the evidence. Am J Hosp Palliat Med, 2016; 33:194–200.
18.
O'DonnellDE, WebbKA, HarleI, NederJA: Pharmacological management of breathlessness in COPD: Recent advances and hopes for the future. Expert Rev Respir Med, 2016; 10:823–834.
19.
RockerG, DownarJ, MorrisonRS: Palliative care for chronic illness: Driving change. CMAJ, 2016; 188:E493–E498.
20.
VermylenJH, SzmuilowiczE, KalhanR: Palliative care in COPD: An unmet area for quality improvement. Int J Chron Obstruct Pulmon Dis, 2015; 10:1543–1551.
21.
CurrowDC, AbernethyAP, KoDN: The active identification and management of chronic refractory breathlessness is a human right. Thorax, 2014; 69:393–394.
22.
EkstromMP, Bornefalk-HermanssonA, AbernethyAP, CurrowDC: Safety of benzodiazepines and opioids in very severe respiratory disease: National prospective study. BMJ, 2014; 348:g445.
23.
AbdallahSJ, Wilkinson-MaitlandC, SaadN, et al.: Effect of morphine on breathlessness and exercise endurance in advanced COPD: A randomised crossover trial. Eur Respir J, 2017; 50. PubMed PMID: 29051274.
24.
EkstromM, NilssonF, AbernethyAA, CurrowDC: Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease: A systematic review. Ann Am Thorac Soc, 2015. PubMed PMID: 25803110.
25.
MularskiRA, RockerG: Managing dyspnea in advanced chronic obstructive pulmonary disease: Balancing all the evidence. Ann Am Thorac Soc, 2015; 12:978–980.
26.
SelzlerAM, WaldJ, SedenoM, et al.: Telehealth pulmonary rehabilitation: A review of the literature and an example of a nationwide initiative to improve the accessibility of pulmonary rehabilitation. Chron Respir Dis, 2017:1479972317724570. PubMed PMID: 28786297.
27.
VermaJY, AmarC, SibbaldS, RockerGM: Improving care for advanced COPD through practice change: Experiences of participation in a Canadian spread collaborative. Chron Respir Dis, 2017:1479972317712720. PubMed PMID: 28612657.
28.
DownarJ, ColmanR, HortonR, et al.: Opioids in COPD: A cause of death or a marker of illness severity?. Eur Respir J, 2016; 48:1520–1521.
29.
GlauserW: Medical-legal concerns over prescribing opioids on the rise. CMAJ, 2017; 189:E1270–E1271.
RockerGM, SimpsonAC, HortonR: Palliative care in advanced lung disease: The challenge of integrating palliation into everyday care. Chest, 2015; 148:801–809.
